464 results on '"Rausch, Steffen"'
Search Results
2. Molekulare Tumorboards in der Uroonkologie – Prostatakarzinom
3. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma
4. Prostaglandin E2 signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production
5. Gegen Nectin-4 gerichtete Antikörper-Wirkstoff-Konjugate als neue Behandlungsoption für Patienten mit metastasiertem Urothelkarzinom
6. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
7. Real world data on IO-based therapy for metastatic renal cell carcinoma
8. Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions
9. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS)
10. Mikro-TESE versus Standard-TESE: für welchen Patienten welches OP-Verfahren?
11. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
12. ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).
13. Adressen
14. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
15. Multiparametrische MRT der Prostata
16. The regulation of FGF23 under physiological and pathophysiological conditions
17. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
18. Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer
19. Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
20. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
21. PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy
22. Urothelial Cancer of the Upper Urinary Tract
23. Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
24. The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
25. Minimal-invasive management of urological complications after kidney transplantation
26. The role of planetary health in urologic oncology.
27. Auswahlverfahren wissenschaftlicher Beiträge zum DGU-Kongress 2021
28. Vitamin A regulates fibroblast growth factor 23 (FGF23)
29. Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer—An Exploratory Analysis of Clinical and Tumor Biological Significance
30. Bilirubin Down-Regulates Oxidative Stress and Fibroblast Growth Factor 23 Expression in UMR106 Osteoblast-Like Cells
31. Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons
32. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin
33. Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions
34. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation
35. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance
36. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study
37. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
38. Occurrence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer.
39. Prospective Analysis of Versatility and User Satisfaction with a Novel Single-Use Cystoscope with Working Channel
40. Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
41. Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
42. Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
43. MP14-19 ALTERATIONS OF INSULIN SIGNALING AND TUMOR BIOLOGY IN UROTHELIAL CARCINOMA OF DIABETIC AND NON-DIABETIC PATIENTS
44. PD36-01 NECTIN-4 PROTEIN EXPRESSION IN MUSCLE INVASIVE BLADDER CANCER - SELECTIVE PREDICTOR OR CONSISTENTLY EXPRESSED IN TUMOR TISSUE?
45. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
46. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
47. Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization
48. Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis
49. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS)
50. Impaired estimated glomerular filtration rate is a significant predictor for non–muscle-invasive bladder cancer recurrence and progression—Introducing a novel prognostic model for bladder cancer recurrence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.